Selective GRB2 SH2 inhibitors as anti-Ras therapy

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Ras signaling is crucial for mitogenic pathways driven by receptor tyrosine kinases (RTKs).
• Dysregulated RTKs and Ras signaling are implicated in various cancers.
• Targeting upstream components of Ras signaling presents a therapeutic strategy for RTK-driven cancers.

Purpose of the Study:

• To investigate the efficacy of CGP78850, a Grb2 SH2 domain inhibitor, in blocking RTK signaling.
• To determine if CGP78850 can inhibit the growth of cancer cells dependent on RTK-Grb2-Ras signaling.
• To explore the downstream effects of Grb2 SH2 inhibition on cell cycle regulators and cellular transformation.

Main Methods:

• Rational drug design was used to develop CGP78850, a specific inhibitor of Grb2 SH2-phosphopeptide interactions.
• In vitro assays assessed specificity against other SH2 domains and SHC PTB domain.
• Cell-based assays evaluated the inhibition of EGFR-Grb2 and Shc-Grb2 interactions, cancer cell growth, and expression of cell cycle inhibitors (p21 and p27).

Main Results:

• CGP78850 specifically inhibits Grb2 SH2 interactions in vitro and blocks EGFR-Grb2 and Shc-Grb2 interactions in cells.
• CGP78850 suppressed the growth of cells transformed by RTKs dependent on Grb2-Ras signaling.
• Inhibition was not observed in cells with oncogenic Raf mutations or activating Ras mutations.
• Grb2 SH2 inhibition led to increased expression of p21(Waf1/Cip1/CAP1) and p27(Kip1) and reversed cellular transformation.

Conclusions:

• CGP78850 is a potent and specific inhibitor of Grb2 SH2 interactions.
• Grb2 SH2 inhibition represents a viable therapeutic strategy for cancers driven by RTK signaling through Grb2.
• CGP78850 demonstrates potential as an anti-cancer agent by reversing transformation and inducing cell cycle arrest.